A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen

Trial Profile

A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Aluminium hydroxide/magnesium hydroxide (Primary) ; Raltegravir (Primary)
  • Indications Heartburn; HIV infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 31 Oct 2013 Planned end date changed from 1 Apr 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top